Research Discipline(s): Clinical, Platform Trials, Critical Care, Hematology
Primary Title: Hematologist and Senior Scientist
Additional Titles & Affiliations: Professor of Medicine
RESEARCH TOPICS
Thombo Inflamation, Anticoagulation, Bleeding/ Transfusion, Sepsis, Covid-19, Pneumonia, Innovated Trial Designs, Hetrogeneity of Treatment Effects in Clinical Trials
Learning while doing: Caring for patients while learning how best treat them through clinical trials
Research Summary
“
Dr. Zarychanski is a Hematologist, Critical Care physician, and Clinician-Scientist at the University of Manitoba and CancerCare Manitoba. His research focuses on the hematologic aspects of critical illness where he leads several national and international randomized trials in the fields of sepsis, anticoagulation and transfusion medicine. He recently served as the Chair for recent adaptive platform trials evaluating anticoagulation strategies in COVID-19 and sepsis, and has contributed to the establishment of a novel trial methods of global collaboration in clinical trials, including the development of the multiplatform randomized trial (mpRCT).
In collaboration with international partners and building on knowledge generated in COVID-19, Dr. Zarychanski, and co-PIs are preparing to launch a large multi-national adaptive RCT evaluating therapeutic-dose heparin in non-Covid community acquired pneumonia. In Canada, he co-chairs a large multicenter RCT studying plasma exchange in septic shock and leads a cluster-crossover trial to evaluate tranexamic to reduce transfusion in major non-cardiac surgery.
“
Goals
Content coming soon
Research Biography
Content coming soon
Achievements
- Physician of the Year. Doctors Manitoba (Manitoba, Canada). For significant contribution to the practice of medicine and/or to the community by a member of Doctors Manitoba. 2023
- Excellence in Research and Mentorship Award. Department of Medical Oncology and Hematology, Cancercare Manitoba (Manitoba, Canada). 2021
- Canadian Hematology Paper of the Year. Canadian Hematology Society. Related to: Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients With Covid-19 / Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. Published: NEJM. August 4, 2021. DOI:10.1056/NEJMoa2105911 and DOI:10.1056/NEJMoa2103417. 2021
- Lyonel G. Israels Research Chair in Hematology ($3,000,000 Endowment) University of Manitoba, Faculty of Health Sciences. 2020
- Mentor of the Year Award. Royal College of Physicians and Surgeons of Canada. Region 2. (Ottawa, Ontario). 2019
- Excellence in Research and Mentorship Award. Department of Medical Oncology and Hematology, Cancercare Manitoba (Manitoba, Canada). 2017
- Doctors Manitoba Scholastic Award (Manitoba, Canada). 2017
- Nominee, Med II Pre-Clerkship Teaching Award. Manitoba Medical Students Association. University of Manitoba. 2017
- Lyonel G. Israels Professorship in Hematology ($2,000,000 Endowment) University of Manitoba, Faculty of Health Sciences. 2016
- 2015: CFPC Continuing Professional Development (CPD) Award College of Family Physicians of Canada, Ottawa, Canada. Award in recognition of “Blood Day” CPD event for Family Physicians in Manitoba & Northwestern Ontario
- Joe Doupe Memorial Lecture. University of Manitoba. September 3, 2015
- 2014: Liam J. Murphy Young Investigator Award. Department of Internal Medicine, University of Manitoba. November, 2014 ($30,000)
- Nomination: Mentor of the Year Royal College of Physicians & Surgeons of Canada. 2013
- Research Citation Award, Society of Critical Care Medicine, Annual Congress. Houston, TX, 2012.
-
Featured Publications
- Writing Committee for the ATTACC/ACTIV-4a/REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, Neal MD…Zarychanski R. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. NEJM/New England Journal of Medicine. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4. PMID: 34351721
- Writing Committee for the REMAP-CAP/ACTIV-4aAATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ, Lawler PR…Zarychanski R. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. NEJM/New England Journal of Medicine. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4. PMID: 34351722
- Bégin P, Callum J, Jamula E…Zarychanski R, Finzi A; CONCOR-1 Study Group, Arnold DM. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine. 2021 Nov;27(11):2012-2024. doi: 10.1038/s41591-021-01488-2. Epub 2021 Sep 9. PMID: 34504336
- Writing Committee for the REMAP-CAP Investigators, Bradbury CA, Lawler PR, Stanworth SJ…Zarychanski R…Gordon AC. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA/Journal of the American Medical Association. 2022 Apr 5;327(13):1247-1259. doi: 10.1001/jama.2022.2910. PMID: 35315874
- Lawler PR, Hochman JS, Zarychanski R. What are Adaptive Platform Clinical Trials and What Role May They Have in Cardiovascular Medicine? Circulation. 2022 Mar;145(9):629-632. doi: 10.1161/CIRCULATIONAHA.121.058113. Epub 2022 Feb 28. PMID: 35226556
- REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F…Zarychanski R…Derde LPG. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine/NEJM. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25. PMID: 33631065
- Boulware DR, Pullen MF, Bangdiwala AS…Zarychanski R…Hullsiek KH. A Randomized Clinical Trial of Hydroxychloroquine as Post-exposure Prophylaxis for Covid-19. NEJM/New England Journal of Medicine. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3. PMID: 32492293.
- Zarychanski R, Houston DS. Assessing Thrombocytopenia in the Intensive Care Unit: The Past, Present, and Future. Hematology Am Soc Hematol Educ Program. 2017. Dec 8;2017(1):660-666. doi: 10.1182/asheducation-2017.1.660. PMID: 29222318
